214 related articles for article (PubMed ID: 26957915)
21. A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer.
Wondergem M; van der Zant FM; van der Ploeg T; Knol RJ
Nucl Med Commun; 2013 Oct; 34(10):935-45. PubMed ID: 23903557
[TBL] [Abstract][Full Text] [Related]
22. No Added Value of
Zacho HD; Jochumsen MR; Langkilde NC; Mortensen JC; Haarmark C; Hendel HW; Jensen JB; Petersen LJ
J Nucl Med; 2019 Dec; 60(12):1713-1716. PubMed ID: 31147402
[TBL] [Abstract][Full Text] [Related]
23.
Ahuja K; Sotoudeh H; Galgano SJ; Singh R; Gupta N; Gaddamanugu S; Choudhary G
J Nucl Med Technol; 2020 Mar; 48(1):9-16. PubMed ID: 31811067
[TBL] [Abstract][Full Text] [Related]
24. Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.
Hurley C; McCarville MB; Shulkin BL; Mao S; Wu J; Navid F; Daw NC; Pappo AS; Bishop MW
Pediatr Blood Cancer; 2016 Aug; 63(8):1381-6. PubMed ID: 27082077
[TBL] [Abstract][Full Text] [Related]
25.
Langsteger W; Rezaee A; Pirich C; Beheshti M
Semin Nucl Med; 2016 Nov; 46(6):491-501. PubMed ID: 27825429
[No Abstract] [Full Text] [Related]
26. ¹⁸F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy.
Bortot DC; Amorim BJ; Oki GC; Gapski SB; Santos AO; Lima MC; Etchebehere EC; Barboza MF; Mengatti J; Ramos CD
Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1730-6. PubMed ID: 22949079
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic performance of
Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
[TBL] [Abstract][Full Text] [Related]
28. ¹⁸F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers.
Withofs N; Grayet B; Tancredi T; Rorive A; Mella C; Giacomelli F; Mievis F; Aerts J; Waltregny D; Jerusalem G; Hustinx R
Nucl Med Commun; 2011 Mar; 32(3):168-76. PubMed ID: 21076343
[TBL] [Abstract][Full Text] [Related]
29. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
30. The Role of 18F-Sodium Fluoride PET/CT Bone Scans in the Diagnosis of Metastatic Bone Disease from Breast and Prostate Cancer.
Kulshrestha RK; Vinjamuri S; England A; Nightingale J; Hogg P
J Nucl Med Technol; 2016 Dec; 44(4):217-222. PubMed ID: 27634981
[TBL] [Abstract][Full Text] [Related]
31. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
32. (18)F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy.
Choi YJ; Hwang HS; Kim HJ; Jeong YH; Cho A; Lee JH; Yun M; Lee JD; Kang WJ
Ann Nucl Med; 2014 May; 28(4):304-13. PubMed ID: 24481823
[TBL] [Abstract][Full Text] [Related]
33. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.
Hahn S; Heusner T; Kümmel S; Köninger A; Nagarajah J; Müller S; Boy C; Forsting M; Bockisch A; Antoch G; Stahl A
Acta Radiol; 2011 Nov; 52(9):1009-14. PubMed ID: 21969709
[TBL] [Abstract][Full Text] [Related]
34. Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
Zattoni F; Agostini E; Cattaneo F; Maruzzo M; Basso U; Zattoni F; Evangelista L
Clin Imaging; 2017; 43():110-116. PubMed ID: 28278446
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic Challenge of Staging Metastatic Bone Disease in the Morbidly Obese Patients: A Primary Study Evaluating the Usefulness of 18F-Sodium Fluoride (NaF) PET-CT.
Usmani S; Marafi F; Ahmed N; Esmail A; Al Kandari F; Van den Wyngaert T
Clin Nucl Med; 2017 Nov; 42(11):829-836. PubMed ID: 28872551
[TBL] [Abstract][Full Text] [Related]
36. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
Qu X; Huang X; Yan W; Wu L; Dai K
Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739
[TBL] [Abstract][Full Text] [Related]
37. [Diagnostic performance of bone scintigraphy and (11)C-Choline PET/CT in the detection of bone metastases in patients with biochemical recurrence of prostate cancer].
Garcia JR; Moreno C; Valls E; Cozar P; Bassa P; Soler M; Alvarez-Moro FJ; Moragas M; Riera E
Rev Esp Med Nucl Imagen Mol; 2015; 34(3):155-61. PubMed ID: 25443648
[TBL] [Abstract][Full Text] [Related]
38. Performance of 18F-fluoride PET or PET/CT for the detection of bone metastases: a meta-analysis.
Shen CT; Qiu ZL; Han TT; Luo QY
Clin Nucl Med; 2015 Feb; 40(2):103-10. PubMed ID: 25290289
[TBL] [Abstract][Full Text] [Related]
39. Comparison of diagnostic ability between (99m)Tc-MDP bone scan and (18)F-FDG PET/CT for bone metastasis in patients with small cell lung cancer.
Lee JW; Lee SM; Lee HS; Kim YH; Bae WK
Ann Nucl Med; 2012 Oct; 26(8):627-33. PubMed ID: 22729551
[TBL] [Abstract][Full Text] [Related]
40. Skeletal PET with 18F-fluoride: applying new technology to an old tracer.
Grant FD; Fahey FH; Packard AB; Davis RT; Alavi A; Treves ST
J Nucl Med; 2008 Jan; 49(1):68-78. PubMed ID: 18077529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]